While the 340B program approaches its 30th birthday this year, we face challenges head on with little help from Congress, the administration or judicial fronts to swing the pendulum back in our favor. Perhaps some feel we are in a dark swamp of despair.

“Keeping Up with the Manufacturer Mayhem,” at 2 p.m. ET Wednesday, Feb. 16. Registration is now open for our covered entities and contract pharmacy partners by contacting your Sentry account manager.

After the spate of rulings in the various federal court cases over contract pharmacy exclusions, the on-again, off-again effort to rein in drug prices by Congress and the Supreme Court hearing arguments over reimbursement cuts to Medicare Part…

Empathy has become a major focus of our customer experience efforts, and it comes at a pivotal moment for 340B.

With the calendar winding down in 2021, we’ll take stock of the biggest stories in a momentous year for the 340B program. We’ll also sprinkle in a dash of what could be in store in the year ahead. 

Covered entities may find a new path to hash out disputes with drugmakers now that the Biden administration has announced plans to replace the existing 340B administrative dispute resolution (ADR) program with a new version.

November brought a series of judicial rulings that seem to suggest the conflict over contract pharmacies will only drag on longer and become more challenging for covered entities.

In April 2021, Sentry made a small change that we hope will pay big dividends for our customers. 

It’s been an eventful month on the 340B front, with the tug of war between manufacturers and covered entities over the role of contract pharmacies.